{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:53:05Z","timestamp":1788580385530,"version":"build-2803163510"},"reference-count":56,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T00:00:00Z","timestamp":1674950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Introduction: There have been disputes in the association between angiotensin receptor blockers (ARB) and the incidence of lung cancer. Our meta-analysis reevaluated this problem from the perspectives of race, age, drug type, comparison objects and smoking. Method: We used the following databases to carry out our literature search: Pubmed, Medline, Cochrane Library, and Ovid (From 1 January 2020 to 28 November 2021). The correlation between ARBs and the incidence rate of lung cancer was calculated by risk ratios (RRs). Confidence intervals were selected with 95% confidence intervals. Results: A total of 10 randomized controlled trials (RCTs), 18 retrospective studies and 3 case-control studies were found to satisfy the inclusion criteria. The use of ARB drugs reduced the incidence of lung cancer. The pooled results of 10 retrospective studies revealed a decreased lung cancer incidence in patients treated with ARBs, especially in patients using Valsartan. A significantly lower lung cancer incidence was found in the ARB drugs than in calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs). Lung cancer occurrence was lower in Asian-based studies, especially in Mongolian-dominated and Caucasian-dominated patient populations. No significant decrease in lung cancer occurrence was found in RCTs or in patients receiving telmisartan, losartan, candesartan, irbesartan, or other placebo or in American and European-dominated patient populations. Conclusion: Compared with ACEIs and CCBs, ARBs significantly reduce the risk of lung cancer, especially in Asian and Mongolian populations. Valsartan has the best effect in reducing the risk of lung cancer in ARB drugs.<\/jats:p>","DOI":"10.3390\/jpm13020243","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T04:31:27Z","timestamp":1675053087000},"page":"243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis"],"prefix":"10.3390","volume":"13","author":[{"given":"Zexu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, School of Medicine, Nanjing University\/Jinling Hospital, Nanjing 210002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/1570161043385556","article-title":"Angiotensin II, cell proliferation and angiogenesis regulator: Biologic and therapeutic implications in cancer","volume":"2","author":"Escobar","year":"2004","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1097\/00029330-200811010-00012","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model","volume":"121","author":"Wang","year":"2008","journal-title":"Chin. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00432-021-03612-8","article-title":"CCL5 production by fibroblasts through a local renin-angiotensin system in malignant melanoma affects tumor immune responses","volume":"147","author":"Nakamura","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.04.019","article-title":"Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer","volume":"64","author":"Datzmann","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: A systematic review","volume":"23","author":"Murray","year":"2012","journal-title":"Cancer Causes Control"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"ARB Trialists Collaboration (2011). Effects of telmisartan, irbesartan, Valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens., 29, 623\u2013635.","DOI":"10.1097\/HJH.0b013e328344a7de"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jch.14187","article-title":"Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in Korea","volume":"23","author":"Jung","year":"2021","journal-title":"J. Clin. Hypertens."},{"key":"ref_12","first-page":"e14788","article-title":"Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Incidence of Lung Cancer: A Retrospective Study","volume":"13","author":"Kumar","year":"2021","journal-title":"Cureus"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lin, S.Y., Lin, C.L., Lin, C.C., Hsu, W.H., Lin, C.D., Wang, I.K., Hsu, C.Y., and Kao, C.H. (2020). Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer-A Nationwide, Population-Based, Propensity Score-Matched Cohort Study. Cancers, 12.","DOI":"10.3390\/cancers12030747"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3961\/jpmph.20.405","article-title":"Association Between Angiotensin II Receptor Blockers and the Risk of Lung Cancer Among Patients With Hypertension From the Korean National Health Insurance Service-National Health Screening Cohort","volume":"53","author":"Moon","year":"2020","journal-title":"J. Prev. Med. Public Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2697","DOI":"10.1136\/bmj.e2697","article-title":"Angiotensin receptor blockers and risk of cancer: Cohort study among people receiving antihypertensive drugs in UK General Practice Research Database","volume":"344","author":"Bhaskaran","year":"2012","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.amjcard.2010.11.026","article-title":"Angiotensin II Receptor Blockers and Risk of Cancer in Patients With Systemic Hypertension","volume":"107","author":"Huang","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/HJH.0b013e3283621ea3","article-title":"Angiotensin receptor blockers: Are they related to lung cancer?","volume":"31","author":"Rao","year":"2013","journal-title":"J. Hypertens."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ijcard.2012.05.096","article-title":"Long-term use of angiotensin II receptor blockers and risk of cancer: A population-based cohort analysis","volume":"167","author":"Wang","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/ajh\/hpw095","article-title":"The Use of Telmisartan and the Incidence of Cancer","volume":"29","author":"Tascilar","year":"2016","journal-title":"Am. J. Hypertens."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","article-title":"Use of angiotensin receptor blockers and the risk of cancer","volume":"123","author":"Pasternak","year":"2011","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events","volume":"358","author":"Heagerty","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"ACTIVE I Investigators, Yusuf, S., Healey, J.S., Pogue, J., Chrolavicius, S., Flather, M., Hart, R.G., Hohnloser, S.H., Joyner, C.D., and A Pfeffer, M. (2011). Irbesartan in Patients with Atrial Fibrillation. N. Engl. J. Med., 364, 928\u2013938.","DOI":"10.1056\/NEJMoa1008816"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on Valsartan or amlodipine: The VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events","volume":"362","author":"Mcmurray","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme","volume":"362","author":"Swedberg","year":"2003","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa060838","article-title":"Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker","volume":"354","author":"Julius","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/S0140-6736(08)61412-9","article-title":"Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebo-controlled trials","volume":"372","author":"Chaturvedi","year":"2008","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(08)61411-7","article-title":"Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial","volume":"372","author":"Klein","year":"2008","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J. Hypertens."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","volume":"359","author":"Devereux","year":"2002","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","article-title":"Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: A population-based case-control study","volume":"74","author":"Hallas","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Azoulay, L., Assimes, T.L., Yin, H., Bartels, D.B., Schiffrin, E.L., and Suissa, S. (2012). Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050893"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/Valsartan: Neprilysin Inhibition 5 Years after PARADIGM-HF","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin Inhibition versus Enalapril in Heart Failure. PARADIGM-HF Investigators and Committees","volume":"371","author":"Mcmurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/Valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: A post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/1470320315607391","article-title":"Angiotensin receptor blockers use and the risk of lung cancer: A meta-analysis","volume":"16","author":"Zhang","year":"2015","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref_44","first-page":"1139","article-title":"Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor","volume":"2","author":"Uemura","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"ref_45","first-page":"1893","article-title":"Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling","volume":"27","author":"Ren","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pros.21049","article-title":"Ets-1 and hypoxia inducible factor-1\u03b1 inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer","volume":"70","author":"Kosaka","year":"2009","journal-title":"Prostate"},{"key":"ref_47","first-page":"193","article-title":"Telmisartan as a peroxisome proliferator-activated receptor-\u03b3 ligand is a new target in the treatment of human renal cell carcinoma","volume":"2","author":"Yoshimura","year":"2009","journal-title":"Mol. Med. Rep."},{"key":"ref_48","first-page":"295","article-title":"Telmisartan is a potent target for prevention and treatment in human prostate cancer","volume":"20","author":"Yoshimura","year":"1994","journal-title":"Oncol. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3892\/etm_00000046","article-title":"Telmisartan inhibits human urological cancer cell growth through early apoptosis","volume":"1","author":"Matsuyama","year":"2010","journal-title":"Exp. Ther. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.18632\/oncotarget.14345","article-title":"The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPK\u03b1\/mTOR pathway in vitro and in vivo","volume":"8","author":"Fujihara","year":"2016","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3892\/ijo.2017.4177","article-title":"Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest","volume":"51","author":"Samukawa","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.3892\/ol.2017.5872","article-title":"Angiotensin II receptor blockers induce autophagy in prostate cancer cells","volume":"13","author":"Woo","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1535370214546267","article-title":"Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells","volume":"240","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.yexcr.2018.04.022","article-title":"Antihypertensive drug-candesartan attenuates TRAIL resistance in human lung cancer via AMPK-mediated inhibition of autophagy flux","volume":"368","author":"Rasheduzzaman","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2020.07.015","article-title":"Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation","volume":"493","author":"Wadsworth","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1159\/000488274","article-title":"The Angiotensin II Type 1 Receptor Antagonist Losartan Affects NHE1-Dependent Melanoma Cell Behavior","volume":"45","author":"Olschewski","year":"2018","journal-title":"Cell. Physiol. Biochem."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/2\/243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:18:52Z","timestamp":1760120332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/2\/243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,29]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jpm13020243"],"URL":"https:\/\/doi.org\/10.3390\/jpm13020243","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,29]]}}}